22 citations,
May 2011 in “European Journal of Cancer” The drug combination was safe and showed promise in treating advanced tumors.
6 citations,
February 2023 in “Advances in Therapy” Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
14 citations,
May 2022 in “Asian Journal of Pharmaceutical Sciences” New hair follicle-targeting treatments show promise for hair disorders but need more research on safety and effectiveness.
3 citations,
May 2018 in “Reproductive Sciences” The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
13 citations,
October 2012 in “InTech eBooks” Nanocarriers could improve how drugs are delivered through the skin but require more research to overcome challenges and ensure safety.
260 citations,
January 2019 in “Pharmaceutics” Niosomes are a promising, stable, and cost-effective drug delivery system with potential for improved targeting and safety.
2 citations,
August 2013 in “The Lancet. Diabetes & endocrinology” The FDA rejected a testosterone drug again due to safety concerns.
January 2019 in “Actas urológicas españolas” Using mirabegron and solifenacin together is safe and more effective for treating overactive bladder than using either drug alone.
December 2013 in “Nursing2023” The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.
19 citations,
October 2020 in “Biomedical Microdevices” Derma rollers show promise for skin improvement and drug delivery, but more research is needed on their safety and effectiveness.
9 citations,
October 2018 in “Journal of Cosmetic and Laser Therapy” Using methods like lasers and microneedling with drugs can improve hair regrowth for alopecia, but more research is needed on safety and best practices.
November 2007 in “Hospital pharmacy” The conclusion is that healthcare professionals should report adverse drug reactions to improve medication safety and patient care.
60 citations,
January 2014 in “Anais Brasileiros De Dermatologia” Nanotechnology in dermatology shows promise for better drug delivery and treatment effectiveness but requires more safety research.
1 citations,
January 2017 in “Springer eBooks” Hair follicles are important for drug delivery through the skin, but better methods are needed to understand and improve this process.
6 citations,
June 2013 in “Toxicological Research” Topical Valproate is safe for human skin and unlikely to cause irritation.
5 citations,
January 2017 in “Nevrologiâ, nejropsihiatriâ, psihosomatika” Sustained-release sodium valproate is effective in treating epilepsy, with some side effects influenced by genetics.
April 2015 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” The safety of the hair loss drug finasteride is unclear due to inadequate reporting in clinical trials.
42 citations,
January 2021 in “Journal of Clinical Medicine” Microneedle arrays with nanotechnology show promise for painless drug delivery through the skin but need more research on safety and effectiveness.
15 citations,
October 2017 in “Journal of Cosmetic and Laser Therapy” FDA-cleared devices may help treat hair loss, but more research needed; consult dermatologist before use.
13 citations,
January 2001 in “Skin pharmacology and physiology” Micro-Imager® helps see how drugs spread in human skin.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
October 2022 in “Journal of experimental and clinical medicine” Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.
122 citations,
March 2013 in “Expert opinion on drug delivery” Optimizing drug delivery to hair follicles is crucial for effective treatment.
84 citations,
March 2004 in “Veterinary Dermatology” Cyclosporin is effective in treating dog skin diseases and has fewer side effects compared to other treatments.
72 citations,
November 2015 in “Multiple Sclerosis and Related Disorders” Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.
34 citations,
January 2020 in “Expert opinion on drug delivery” New methods like microneedling and nanoparticles can improve hair loss treatments.
20 citations,
August 2014 in “Therapeutic delivery” The transfollicular route shows promise for noninvasive, targeted drug delivery but needs more research.
9 citations,
October 2018 in “Elsevier eBooks” Nanotechnology is improving drug delivery and targeting, with promising applications in cancer treatment, gene therapy, and cosmetics, but challenges remain in ensuring precise delivery and safety.
5 citations,
December 2023 in “Materials” Organic and biogenic nanocarriers can improve drug delivery but face challenges like consistency and safety.
3 citations,
March 2017 in “Regulatory toxicology and pharmacology” Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.